TY - RPRT
KW - Naloxone -- Therapeutic Use
KW - Drug Overdose -- drug therapy
KW - Narcotic Antagonists -- Therapeutic Use
KW - Analgesics, Opioid -- Adverse Effects
KW - Self Care -- methods
KW - Health Services Accessibility
KW - Comparative Effectiveness Research
KW - Cost-Benefit Analysis
KW - Guidelines as Topic
AU - Yi-Sheng Chao
AU - Hannah Loshak
A1 - 
AB - Opioid overdose can induce acute respiratory and central nervous system depression that may lead to death. Recently the numbers of opioid-related deaths or hospitalizations have increased in Canada and there is an ongoing opioid crisis. Naloxone, a medication that temporarily blocks the effects of opioids, has been advocated for a wider use in the communities. Naloxone works by competing for opioid receptors with opioids and remains active in the body for 20 to 90 minutes, shorter than most opioids. Without opioids, naloxone has little pharmacologic activity. Data from noncomparative studies suggest that naloxone use in a home or community setting for opioid overdose is associated with a low mortality rate. In Canada, take-home naloxone kits are available at most pharmacies without a prescription and are free in some provinces. This report aims to update a previous CADTH review on the clinical effectiveness and cost effectiveness of the administration of naloxone in a home or community setting, as well as to identify evidence-based guidelines for its use.
BT - CADTH rapid response report: summary with critical appraisal,; Variation: Rapid response report (Canadian Agency for Drugs and Technologies in Health)
C4 - This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
C5 - Grey Literature; Education & Workforce; Financing & Sustainability; Opioids & Substance Use
CY - Ottawa
JF - CADTH rapid response report: summary with critical appraisal,; Variation: Rapid response report (Canadian Agency for Drugs and Technologies in Health)
LA - English
M1 - Report
N2 - Opioid overdose can induce acute respiratory and central nervous system depression that may lead to death. Recently the numbers of opioid-related deaths or hospitalizations have increased in Canada and there is an ongoing opioid crisis. Naloxone, a medication that temporarily blocks the effects of opioids, has been advocated for a wider use in the communities. Naloxone works by competing for opioid receptors with opioids and remains active in the body for 20 to 90 minutes, shorter than most opioids. Without opioids, naloxone has little pharmacologic activity. Data from noncomparative studies suggest that naloxone use in a home or community setting for opioid overdose is associated with a low mortality rate. In Canada, take-home naloxone kits are available at most pharmacies without a prescription and are free in some provinces. This report aims to update a previous CADTH review on the clinical effectiveness and cost effectiveness of the administration of naloxone in a home or community setting, as well as to identify evidence-based guidelines for its use.
PP - Ottawa
PY - 2019
RN - http://www.ncbi.nlm.nih.gov/books/NBK554744/
SN - Series 1922-8147; National Library: 101766038
T1 - Administration of naloxone in a home or community setting: A review of the clinical effectiveness, cost-effectiveness, and guidelines. (CADTH rapid response report: summary with critical appraisal)
T2 - CADTH rapid response report: summary with critical appraisal,; Variation: Rapid response report (Canadian Agency for Drugs and Technologies in Health)
TI - Administration of naloxone in a home or community setting: A review of the clinical effectiveness, cost-effectiveness, and guidelines. (CADTH rapid response report: summary with critical appraisal)
U1 - Grey Literature; Education & Workforce; Financing & Sustainability; Opioids & Substance Use
U4 - This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
U5 - http://www.ncbi.nlm.nih.gov/books/NBK554744/
UR - http://www.ncbi.nlm.nih.gov/books/NBK554744/
VO - Series 1922-8147; National Library: 101766038
Y1 - 2019
ER -